Biotech

All Articles

Amgen files first stage 3 gain for $400M eczema medication

.Amgen has discussed (PDF) the 1st phase 3 information on its $400 thousand chronic eczema medicine,...

Biogen, UCB report phase 3 lupus win after stopping working earlier test

.Biogen as well as UCB's rely on developing in to period 3 on the back of an unsuccessful study look...

Aptadir hopes new RNA preventions can turn around challenging cancers cells

.Italian biotech Aptadir Rehabs has actually released with the pledge that its pipe of preclinical R...

Wave surfs DMD excellence to regulatory authorities' doors, sending out stock up

.Surge Lifestyle Sciences has actually satisfied its own goal in a Duchenne muscular dystrophy (DMD)...

Sanofi picks brand-new CSO coming from in-stealth biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, using up...

Achilles droplets tissue therapy course, supports for unemployments after overlooking 'industrial feasibility' goals

.Achilles Therapeutics has destroyed its technique. The British biotech is actually stopping work on...

Aligos advertises stage 2 MASH gain, lowering liver body fat around 46%

.Aligos Rehabs is trumpeting a midstage win in metabolic-dysfunction linked steatohepatitis (MASH) a...

Basilea ratings $268M BARDA funding for antifungals, prescription antibiotics

.Basilea Pharmaceutica's job establishing new antifungals has acquired a considerable improvement fr...

Capricor markets Europe legal rights to late-stage DMD treatment for $35M

.Possessing presently scooped up the USA liberties to Capricor Rehabs' late-stage Duchenne muscle dy...

FDA junks adcomm for Applied's unusual ailment drug

.After pushing back the choice date for Applied Rehabs' metabolic disorder medicine govorestat, the ...